|Items||Size （2mg）||Size（5mg X 2）|
|Particle size||2 μm||2 μm|
|Physical appearance||Powder mixture||Powder mixture|
|Amount of Coupled Protein||>798 pmol (60 μg) Anti-RBD antibody/mg beads||>798 pmol (60 μg) Anti-RBD antibody/mg beads|
|Binding Capacity||>192 pmol (10 μg) Spike RBD/mg beads||>192 pmol (10 μg) Spike RBD/mg beads|
|Formulation||PBS, pH7.4, with 10% Trehalose||PBS, pH7.4, with 10% Trehalose|
|Reconstitution||2 mL ultrapure water (1 mg beads/mL)||5 mL ultrapure water (1 mg beads/mL)|
Upon receipt, please store the Beads at -20℃. The shelf life is 1 year at -20 ℃.
Please avoid more than 3 freeze-thaw cycles. Immediate use after reconstitution is highly recommended.
a) Reconstitute the Beads following the COA. Wash and re-suspend the beads to a certain concentration by adding your dilution buffer.
b) Add the prepared beads to your samples.
c) Beads can be separated from your samples afterwards using a magnetic plate.
Immobilized 73.1 μg Anti-RBD antibody/1mg beads can bind SARS-CoV-2 Spike RBD (Cat. No. SPD-C5259) with an EC50 of 0.4705 μg/mL (QC tested).
Emerging VoCs, Lambda, Delta, Beta, Alpha mutants and so on, including RBD, S trimer, S1, NTD, NP, etc. These mutants are of high purity and bioactivity and can be used to evaluate the efficacy of the antibodies and vaccination.
ELISA kits for neutralizing antibody titer assay, binding antibody titer assay, antibody isotype assay, antigen titer assay and inhibitor screening, etc., which can accelerate the research and development of anti-SARS-CoV-2 drugs and vaccines.
50+ targets designed for CAR detection, including PE/FITC/biotin labeled proteins. The key reagents for CD19 and BCMA were FDA DMF filed which can support your IND, NDA and BLA process.
Full length multi-pass TPs with stabilized structure and high bioactivity for immunization, antibody screening, cell based assay and CAR detection, including hot CD20, Claudin 18.2， CD133, GPRC5D，CCR8, CCR5, etc.
This web search service is supported by Google Inc.